Ryan Wong's most recent trade in Sarepta Therapeutics Inc was a trade of 13,272 Common Stock done at an average price of $22.2 . Disclosure was reported to the exchange on Sept. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Ryan H. Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.22 per share. | 04 Sep 2026 | 13,272 | 121,792 (0%) | 0% | 22.2 | 294,904 | Common Stock |
| Sarepta Therapeutics Inc | Ryan H. Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.03 per share. | 11 Mar 2026 | 256 | 135,064 (0%) | 0% | 17.0 | 4,360 | Common Stock |
| Sarepta Therapeutics Inc | Ryan H. Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.95 per share. | 09 Mar 2026 | 162 | 135,433 (0%) | 0% | 17.0 | 2,746 | Common Stock |
| Sarepta Therapeutics Inc | Ryan H. Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.95 per share. | 09 Mar 2026 | 113 | 135,320 (0%) | 0% | 16.9 | 1,915 | Common Stock |
| Sarepta Therapeutics Inc | Ryan H. Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.20 per share. | 02 Mar 2026 | 450 | 135,595 (0%) | 0% | 16.2 | 7,290 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.96 per share. | 01 Dec 2025 | 80 | 136,123 (0%) | 0% | 21.0 | 1,677 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.96 per share. | 01 Dec 2025 | 78 | 136,045 (0%) | 0% | 21.0 | 1,635 | Common Stock |
| Sarepta Therapeutics Inc | Ryan Wong | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2025 | 93,875 | 111,203 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Wong | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2025 | 25,000 | 136,203 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ryan Wong | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.42 per share. | 31 Jul 2025 | 327 | 17,328 (0%) | 0% | 16.4 | 5,369 | Common Stock |